Volver a Agenda
LS03 Considering Benefit-Risk Assessment in New Drug Applications
Session Chair(s)
Mamoru Narukawa, PHD, RPH
Professor
Kitasato University, Japan
Speaker(s)
Katsuhiko Ichimaru
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Review Director, Office of New Drug IV
Yuko Asahara
Novartis Pharma K.K., Japan
Global Drug Development Div, Regulatory Writing and Submissions, Head
Mamoru Narukawa, PHD, RPH
Kitasato University, Japan
Professor
¿Tiene una cuenta?